fda reversal tirzepatide GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration? Weight Loss

BioWorld - Saturday, July 25, 2026 Breaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaSee today's BioWorld Science Home BPC-157 lessens effects of alcohol intoxication and withdrawal To read the full story, subscribe or sign in

patent on tirzepatide is expected to expire in 2036, while additional patents covering formulations, delivery devices, and methods of treatment could extend protection until approximately 2041

Muscle preservation becomes the key focus for this age group, making protein intake and strength training non-negotiable components of any treatment plan

Belfort R, Harrison SA, Brown K, et al